Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol

A report from the JWiTS Group

Takaharu Oue, Masahiro Fukuzawa, Hajime Okita, Hideo Mugishima, Hiroshi Horie, Jun Ichi Hata, Masahiro Saito, Miwako Nozaki, Motoaki Chin, Hisaya Nakadate, Shiro Hinotsu, Tsugumichi Koshinaga, Yasuhiko Kaneko, Yoshihiro Kitano, Yukichi Tanaka

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: In 1996, the Japan Wilms Tumor Study (JWiTS) group was founded to elucidate the efficacy and safety of the regimen established by the National Wilms Tumor Study (NWTS) group in the USA, and a multicenter cooperative study (JWiTS-1) was started in Japan. This report reviews the results of JWiTS-1. Methods: A total of 307 patients with malignant renal tumor were enrolled in the JWiTS-1 study between 1996 and 2005. Central pathological diagnosis and follow-up data were available in 210 cases. The protocol regimens were similar to the NWTS-5 regimens. Clinical stage was classified according to the Japanese Staging System. Results: Five-year overall survival (OS) rate was 91.1% for nephroblastoma, 72.9% for clear cell sarcoma of the kidney (CCSK), and 22.2% for rhabdoid tumor of the kidney (RTK). In the nephroblastoma patients, 5-year OS was 90.5% for stage I disease, 92.2% for stage II, 90.9% for stage III, 86.7% for stage IV, and 78.7% for stage V. Conclusions: The OS of patients in the JWiTS-1 study were comparable with the results of other multicenter studies in the USA and Europe. The outcome for patients with nephroblastoma and CCSK was fair. In contrast, the cure rate for those with RTK was not satisfactory. New treatment strategies are needed for patients with RTK.

Original languageEnglish
Pages (from-to)923-929
Number of pages7
JournalPediatric Surgery International
Volume25
Issue number11
DOIs
Publication statusPublished - Nov 2009
Externally publishedYes

Fingerprint

Wilms Tumor
Japan
Pediatrics
Kidney
Rhabdoid Tumor
Neoplasms
Clear Cell Sarcoma
Multicenter Studies
Survival
Survival Rate
Safety

Keywords

  • Clinical trials
  • Group study
  • Japan
  • Survival
  • Wilms tumor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Surgery

Cite this

Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol : A report from the JWiTS Group. / Oue, Takaharu; Fukuzawa, Masahiro; Okita, Hajime; Mugishima, Hideo; Horie, Hiroshi; Hata, Jun Ichi; Saito, Masahiro; Nozaki, Miwako; Chin, Motoaki; Nakadate, Hisaya; Hinotsu, Shiro; Koshinaga, Tsugumichi; Kaneko, Yasuhiko; Kitano, Yoshihiro; Tanaka, Yukichi.

In: Pediatric Surgery International, Vol. 25, No. 11, 11.2009, p. 923-929.

Research output: Contribution to journalArticle

Oue, T, Fukuzawa, M, Okita, H, Mugishima, H, Horie, H, Hata, JI, Saito, M, Nozaki, M, Chin, M, Nakadate, H, Hinotsu, S, Koshinaga, T, Kaneko, Y, Kitano, Y & Tanaka, Y 2009, 'Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol: A report from the JWiTS Group', Pediatric Surgery International, vol. 25, no. 11, pp. 923-929. https://doi.org/10.1007/s00383-009-2449-0
Oue, Takaharu ; Fukuzawa, Masahiro ; Okita, Hajime ; Mugishima, Hideo ; Horie, Hiroshi ; Hata, Jun Ichi ; Saito, Masahiro ; Nozaki, Miwako ; Chin, Motoaki ; Nakadate, Hisaya ; Hinotsu, Shiro ; Koshinaga, Tsugumichi ; Kaneko, Yasuhiko ; Kitano, Yoshihiro ; Tanaka, Yukichi. / Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol : A report from the JWiTS Group. In: Pediatric Surgery International. 2009 ; Vol. 25, No. 11. pp. 923-929.
@article{f3a16cbf502e41a893b5da731265f4f7,
title = "Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol: A report from the JWiTS Group",
abstract = "Purpose: In 1996, the Japan Wilms Tumor Study (JWiTS) group was founded to elucidate the efficacy and safety of the regimen established by the National Wilms Tumor Study (NWTS) group in the USA, and a multicenter cooperative study (JWiTS-1) was started in Japan. This report reviews the results of JWiTS-1. Methods: A total of 307 patients with malignant renal tumor were enrolled in the JWiTS-1 study between 1996 and 2005. Central pathological diagnosis and follow-up data were available in 210 cases. The protocol regimens were similar to the NWTS-5 regimens. Clinical stage was classified according to the Japanese Staging System. Results: Five-year overall survival (OS) rate was 91.1{\%} for nephroblastoma, 72.9{\%} for clear cell sarcoma of the kidney (CCSK), and 22.2{\%} for rhabdoid tumor of the kidney (RTK). In the nephroblastoma patients, 5-year OS was 90.5{\%} for stage I disease, 92.2{\%} for stage II, 90.9{\%} for stage III, 86.7{\%} for stage IV, and 78.7{\%} for stage V. Conclusions: The OS of patients in the JWiTS-1 study were comparable with the results of other multicenter studies in the USA and Europe. The outcome for patients with nephroblastoma and CCSK was fair. In contrast, the cure rate for those with RTK was not satisfactory. New treatment strategies are needed for patients with RTK.",
keywords = "Clinical trials, Group study, Japan, Survival, Wilms tumor",
author = "Takaharu Oue and Masahiro Fukuzawa and Hajime Okita and Hideo Mugishima and Hiroshi Horie and Hata, {Jun Ichi} and Masahiro Saito and Miwako Nozaki and Motoaki Chin and Hisaya Nakadate and Shiro Hinotsu and Tsugumichi Koshinaga and Yasuhiko Kaneko and Yoshihiro Kitano and Yukichi Tanaka",
year = "2009",
month = "11",
doi = "10.1007/s00383-009-2449-0",
language = "English",
volume = "25",
pages = "923--929",
journal = "Pediatric Surgery International",
issn = "0179-0358",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol

T2 - A report from the JWiTS Group

AU - Oue, Takaharu

AU - Fukuzawa, Masahiro

AU - Okita, Hajime

AU - Mugishima, Hideo

AU - Horie, Hiroshi

AU - Hata, Jun Ichi

AU - Saito, Masahiro

AU - Nozaki, Miwako

AU - Chin, Motoaki

AU - Nakadate, Hisaya

AU - Hinotsu, Shiro

AU - Koshinaga, Tsugumichi

AU - Kaneko, Yasuhiko

AU - Kitano, Yoshihiro

AU - Tanaka, Yukichi

PY - 2009/11

Y1 - 2009/11

N2 - Purpose: In 1996, the Japan Wilms Tumor Study (JWiTS) group was founded to elucidate the efficacy and safety of the regimen established by the National Wilms Tumor Study (NWTS) group in the USA, and a multicenter cooperative study (JWiTS-1) was started in Japan. This report reviews the results of JWiTS-1. Methods: A total of 307 patients with malignant renal tumor were enrolled in the JWiTS-1 study between 1996 and 2005. Central pathological diagnosis and follow-up data were available in 210 cases. The protocol regimens were similar to the NWTS-5 regimens. Clinical stage was classified according to the Japanese Staging System. Results: Five-year overall survival (OS) rate was 91.1% for nephroblastoma, 72.9% for clear cell sarcoma of the kidney (CCSK), and 22.2% for rhabdoid tumor of the kidney (RTK). In the nephroblastoma patients, 5-year OS was 90.5% for stage I disease, 92.2% for stage II, 90.9% for stage III, 86.7% for stage IV, and 78.7% for stage V. Conclusions: The OS of patients in the JWiTS-1 study were comparable with the results of other multicenter studies in the USA and Europe. The outcome for patients with nephroblastoma and CCSK was fair. In contrast, the cure rate for those with RTK was not satisfactory. New treatment strategies are needed for patients with RTK.

AB - Purpose: In 1996, the Japan Wilms Tumor Study (JWiTS) group was founded to elucidate the efficacy and safety of the regimen established by the National Wilms Tumor Study (NWTS) group in the USA, and a multicenter cooperative study (JWiTS-1) was started in Japan. This report reviews the results of JWiTS-1. Methods: A total of 307 patients with malignant renal tumor were enrolled in the JWiTS-1 study between 1996 and 2005. Central pathological diagnosis and follow-up data were available in 210 cases. The protocol regimens were similar to the NWTS-5 regimens. Clinical stage was classified according to the Japanese Staging System. Results: Five-year overall survival (OS) rate was 91.1% for nephroblastoma, 72.9% for clear cell sarcoma of the kidney (CCSK), and 22.2% for rhabdoid tumor of the kidney (RTK). In the nephroblastoma patients, 5-year OS was 90.5% for stage I disease, 92.2% for stage II, 90.9% for stage III, 86.7% for stage IV, and 78.7% for stage V. Conclusions: The OS of patients in the JWiTS-1 study were comparable with the results of other multicenter studies in the USA and Europe. The outcome for patients with nephroblastoma and CCSK was fair. In contrast, the cure rate for those with RTK was not satisfactory. New treatment strategies are needed for patients with RTK.

KW - Clinical trials

KW - Group study

KW - Japan

KW - Survival

KW - Wilms tumor

UR - http://www.scopus.com/inward/record.url?scp=70350198043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350198043&partnerID=8YFLogxK

U2 - 10.1007/s00383-009-2449-0

DO - 10.1007/s00383-009-2449-0

M3 - Article

VL - 25

SP - 923

EP - 929

JO - Pediatric Surgery International

JF - Pediatric Surgery International

SN - 0179-0358

IS - 11

ER -